BridgeBio Pharma
BBIO
457 hedge funds and large institutions have $14.9B invested in BridgeBio Pharma in 2026 Q1 according to their latest regulatory filings, with 90 funds opening new positions, 181 increasing their positions, 133 reducing their positions, and 55 closing their positions.
497% more call options, than puts
Call options by funds: $780M | Put options by funds: $131M
64% more first-time investments, than exits
New positions opened: 90 | Existing positions closed: 55
36% more repeat investments, than reductions
Existing positions increased: 181 | Existing positions reduced: 133
6% more funds holding
Funds holding: 432 → 457 (+25)
1.25% more ownership
Funds ownership: 99.16% → 100.4% (+1.2%)
4% more capital invested
Capital invested by funds: $14.4B → $14.9B (+$533M)
27% less funds holding in top 10
Funds holding in top 10: 22 → 16 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$179M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$158M |
| 3 |
Jane Street
New York
|
+$103M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$88.4M |
| 5 |
Two Sigma Investments
New York
|
+$85.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$185M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$84.9M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
-$52.3M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$38.7M |
| 5 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
-$33.4M |
BBIO Hedge Fund Activity: Q1 2026 in Review
457 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q1 2026, worth a combined $14.9B — up 3.7% from $14.4B a quarter earlier.
Buyers outnumbered sellers: 90 funds opened new BBIO positions and 55 closed out — a net gain of 35 holders — while 181 added to existing stakes and 133 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $179M. The largest seller was Viking Global Investors, cutting an estimated $185M.
- 457 institutional investors held BridgeBio Pharma (BBIO) as of Q1 2026, up from 432 in Q4 2025.
- Funds reported $14.9B of BridgeBio Pharma stock for Q1 2026, up 3.7% quarter-over-quarter.
- 90 funds opened new BridgeBio Pharma positions in Q1 2026 and 55 closed out, a net change of +35 holders.
- The largest BridgeBio Pharma buyer in Q1 2026 was Citadel Advisors, an estimated $179M added.
- The largest BridgeBio Pharma seller in Q1 2026 was Viking Global Investors, an estimated $185M sold.
Based on aggregated 13F filings for Q1 2026.